335620-96-7

Basic information

• Product Name: 3-benzyl-7-(phenylsulfonyl)-9-oxa-3,7-diazabicyclo[3.3.1]nonane
• Synonyms: 3-Benzyl-7-(phenylsulfonyl)-9-oxa-3,7-diazabicyclo[3.3.1]nonane; 9-oxa-3,7-diazabicyclo[3.3.1]nonane, 3-(phenylmethyl)-7-(phenylsulfonyl)-
• CAS NO: 335620-96-7
• Molecular Formula: C₁₉H₂₂N₂O₃S
• Molecular Weight: 358.4546
• Mol File: 335620-96-7.mol

Chemical Properties

• Boiling Point: 508.436°C at 760 mmHg
• Flash Point: 261.293°C
• Density: 1.283g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.619
• CAS DataBase Reference: 3-benzyl-7-(phenylsulfonyl)-9-oxa-3,7-diazabicyclo[3.3.1]nonane(CAS DataBase Reference)
• NIST Chemistry Reference: 3-benzyl-7-(phenylsulfonyl)-9-oxa-3,7-diazabicyclo[3.3.1]nonane(335620-96-7)
• EPA Substance Registry System: 3-benzyl-7-(phenylsulfonyl)-9-oxa-3,7-diazabicyclo[3.3.1]nonane(335620-96-7)

Safety Data

• Hazardous Substances Data: 335620-96-7(Hazardous Substances Data)

Upstream product

• 335621-26-6 1-benzyl-5-(phenylsulfonyl)-1,5-diazoctane-3,7-diol 
• 100-46-9 benzylamine 
• 864448-26-0 (meso)-4-benzenesulfonyl-1-benzylpiperazine-2,6-dicarboxylic acid diethyl ester 
• 1433989-98-0 (1-benzyl-4-(phenylsulfonyl)piperazine-2,6-diyl)dimethanol 
• 864448-25-9 (S)-ethyl 2-bromo-3-(N-((R)-2-bromo-3-ethoxy-3-oxopropyl)phenyl-sulfonamido)propanoate 
• 938-05-6 dibromamine-B 
• 98-10-2 benzenesulfonamide 
• 864448-27-1 cis-(1-benzyl-4-(phenylsulfonyl)piperazine-2,6-diyl)dimethanol 
• 30569-34-7 N,N-bis(oxiran-2-ylmethyl)benzenesulfonamide 
• 91639-34-8 2,6-bis(iodomethyl)-4-(phenylsulfonyl)morpholine 

Downstream Products

• 473584-09-7 7-benzyl-9-oxa-3,7-diazabicyclo[3.3.1]nonane 
• 335620-98-9 tert-butyl 7-benzyl-9-oxa-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate 
• 335620-99-0 tert-butyl 7-benzyl-9-oxa-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate hydrochloride 
• 335621-00-6 tert-butyl 9-oxa-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate hydrochloride 
• 864448-39-5 9-benzyl-3-oxa-7,9-diazabicyclo[3.3.1]nonane 
• 868408-12-2 (E)-(5-chloro-2-{3-[9-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-3-oxopropenyl}-phenyl)-carbamic acid tert-butyl ester 
• 868408-15-5 (E)-(5-chloro-2-{3-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-3-oxopropenyl}-phenyl)-carbamic acid tert-butyl ester 
• 868408-04-2 N-(5-chloro-2-{2-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-2-oxoethoxy}-phenyl)acetamide 
• 864448-44-2 9-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]nonane-7-carboxylic acid tert-butyl ester 
• 868408-10-0 2-chloro-1-[9-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl]-ethanone 
• 868408-06-4 2-chloro-1-[7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl]-ethanone 
• 864448-40-8 9-benzyl-3-oxa-7,9-diazabicyclo[3.3.1]nonane-7-carboxylic acid tert-butyl ester 
• 864448-43-1 7-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]nonane 
• 864448-45-3 9-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]nonane 

Relevant articles and documents

ALKYLATED PIPERAZINE COMPOUNDS

Alkylated piperazine compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

3,7-DIAZABICYCLO[3.3.1]NONANE AND 9-OXA-3,7-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES

The present invention relates to 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7- diazabicyclo[3.3.1 ]nonane derivatives of formula (I) wherein Ar1 and Ar2 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.

NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS

There is provided compounds of formula I, [Chemical formula should be inserted here. Please see paper copy] wherein R1 to R4 , R41 to R46 and Z have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias

COMPOUNDS AS CCRI ANTAGONISTS

A compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the symbols have meaning as defined, which are antagonists of CCR-1 and which find use pharmaceutically for treatment of diseases and conditions in which CCR-1 is implicated, e.g. inflammatory diseases.

NOVEL 2,5-DISUBSTITUTED PYRIMIDINE DERIVATIVES

The invention relates to novel 2,5-disubstituted pyrimidine derivatives, which stimulate the soluble guanylate cyclase, method for production and use thereof for the production of medicaments, in particular medicaments for the treatment of central nervous system diseases.

Oxabispidine compounds useful in the treatment of cardiac arrhyythmias

There is provided compounds of formula I, wherein R1, R2, R3, R4, R41to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.